Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA:603456)
China flag China · Delayed Price · Currency is CNY
15.73
+0.99 (6.72%)
Aug 4, 2026, 3:00 PM CST

SHA:603456 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
5,1485,4165,0865,4065,1813,823
Other Revenue
65.3892.6874.24117.58264.29240.52
5,2135,5095,1615,5235,4454,063
Revenue Growth
-1.03%6.74%-6.57%1.44%34.01%53.49%
Cost of Revenue
3,4343,6463,5713,5243,6232,746
Gross Profit
1,7781,8631,5901,9991,8221,317
Selling, General & Admin
516.14497.92513.31524.15480.09383.42
Research & Development
258.51256.99314.91330.83287.38173.36
Other Operating Expenses
43.9851.0129.4721.9734.6726.52
Operating Expenses
819.04791.11874.34896.32796.43590.87
Operating Income
959.451,072715.311,1031,026725.97
Interest Expense
-8.4-10.12-19.38-21.73-22.38-24.87
Interest & Investment Income
5144.8786.0691.8215.2768.74
Currency Exchange Gain (Loss)
-10.53-12.9112.529.0297.03-18.36
Other Non Operating Income (Expenses)
-26.33-2.02-1.33-4.27-2.02-2.29
EBT Excluding Unusual Items
965.181,091793.181,1781,114749.19
Impairment of Goodwill
-75.52-76-21.511.32-0.87-10.86
Gain (Loss) on Sale of Investments
1.84--8.13-19.36-35.22-1.39
Gain (Loss) on Sale of Assets
-7.25-6.38-13.54-4.03-8.85-16.57
Asset Writedown
-135.82-98.09-39.11-0.13--5.54
Other Unusual Items
6.148.5319.7225.2635.0329.92
Pretax Income
754.57919.45730.61,1811,104744.74
Income Tax Expense
171.94190.91123.53149.27182.85110.59
Earnings From Continuing Operations
582.62728.54607.071,031920.97634.15
Minority Interest in Earnings
9.011.53-0.971.880.2-0.25
Net Income
591.64730.07606.11,033921.17633.9
Net Income to Common
591.64730.07606.11,033921.17633.9
Net Income Growth
-9.94%20.46%-41.34%12.17%45.32%66.56%
Shares Outstanding (Basic)
885890891891830823
Shares Outstanding (Diluted)
885890891891830834
Shares Change
-0.44%-0.11%0.07%7.33%-0.50%3.00%
EPS (Basic)
0.670.820.681.161.110.77
EPS (Diluted)
0.670.820.681.161.110.76
EPS Growth
-9.54%20.59%-41.38%4.50%46.05%61.70%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
928.551,164102.69430.88511.9997.64
Free Cash Flow Per Share
1.051.310.120.480.620.12
Dividend Per Share
0.1000.3000.3000.5000.4000.250
Dividend Growth
-80.00%0%-40.00%25.00%60.00%25.00%
Gross Margin
34.12%33.81%30.80%36.19%33.47%32.41%
Operating Margin
18.40%19.45%13.86%19.96%18.84%17.87%
Profit Margin
11.35%13.25%11.74%18.71%16.92%15.60%
Free Cash Flow Margin
17.81%21.13%1.99%7.80%9.40%2.40%
EBITDA
1,3851,4801,1181,4791,3691,017
EBITDA Margin
26.57%26.87%21.67%26.77%25.13%25.04%
D&A For EBITDA
425.45408.43403.12376.06342.67291.37
EBIT
959.451,072715.311,1031,026725.97
EBIT Margin
18.40%19.45%13.86%19.96%18.84%17.87%
Effective Tax Rate
22.79%20.76%16.91%12.64%16.56%14.85%
Revenue as Reported
5,2135,5095,1615,5235,4454,063